At present, the third-generation EGFR-TKIs have been recommended by the authoritative lung cancer diagnosis and treatment guidelines of the United States and China as the first choice for the treatment of NSCLC with EGFR-sensitive mutation and T790M resistance mutation (45). Here, EGFR is linked to non-small cell lung carcinoma.